BackTelix Pharmaceuticals Limited Overview

Telix Pharmaceuticals Limited Common Stock

Track Telix Pharmaceuticals Limited's common stock ($490M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$490.71M
↑ 4.19% YoYΔ $19.74M vs prior year quarter

Peer trimmed avg / median

Loading

Telix Pharmaceuticals Limited Common Stock History

Loading

Telix Pharmaceuticals Limited vs. peers: Common Stock Comparison

Loading

Telix Pharmaceuticals Limited Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Telix Pharmaceuticals Limited (TLPPF) FAQ

As of the most recent data (June 2026), TLPPF shows a common stock of $490M. That compares with $470M in the prior-year period — up 4.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TLPPF's common stock is now $490M (was $470M) — a 4.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Telix Pharmaceuticals Limited is outperforming or lagging.

Tracking TLPPF's common stock over time shows whether Telix Pharmaceuticals Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $490M That compares with $470M in the prior-year period — up 4.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Telix Pharmaceuticals Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $490M) with ownership activity and broader fundamentals.

Telix Pharmaceuticals Limited's common stock is $490M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.